Literature DB >> 12164087

The changes in cardiac dimensions and function in patients with end stage renal disease undergoing hemodialysis.

Dong Won Lee1, Yong Beom Kim, Seoung Jae An, Yoo Suck Jung, Ihm Soo Kwak, Yung Woo Shin, Ha Yeon Rha.   

Abstract

BACKGROUND: It is absolutely necessary to evaluate cardiac function on starting and during hemodialysis in patients with end stage renal disease. In this study, we tried to determinate the changes of cardiac function associated with hemodialysis.
METHODS: Twenty patients with end stage renal disease, who had been in a hemodialysis program from February, 1997 to August, 1999 in Pusan National University Hospital, were enrolled. They were examined with echocardiography and gated blood pool scintigraphy on starting hemodialysis and after follow-up. The data were analyzed by paired t-test.
RESULTS: The patients were 46.2 +/- 16.8 years old and male to female ratio was 8:12. The underlying diseases were diabetes mellitus (n = 10), hypertension, glomerulonephritis and others. The duration of symptoms associated with end stage renal disease and underlying diseases was 3.4 +/- 2.6 years and the duration of hemodialysis was 13.8 +/- 7.0 months. The LVEDID, LVESID and RVC decreased significantly (-6.10, -7.80 and -20.00%, respectively, p < 0.05) with no significant changes for LAD, IVS, PWT and EF (p > 0.05). In ten cases associated with diabetes, LVEDID decreased (-7.90%, p < 0.05). In twelve cases associated with cardiac diseases, LVEDID and LVESID decreased (-8.60 and -10.50%, respectively, p < 0.05). In four cases associated with diabetes without cardiac diseases, LAD decreased (-5.10%, p < 0.05) and in four cases associated with cardiac diseases without diabetes there were no significant changes in cardiac dimensions and EF. In seven cases associated with diabetes and cardiac diseases, LVEDID decreased (-10.50%, p < 0.05). The EF on gated blood pool scintigraphy decreased (-0.9%, p < 0.05) as a whole while it increased (5.90%, p < 0.05) in the cases associated with diabetes and cardiac diseases.
CONCLUSION: During the early hemodialysis stage of end stage renal disease, we found a change of concentric left ventricular hypertrophy and relatively preserved left ventricular function. Furthermore, we can expect that adequate hemodialysis--with dry weight as low as possible--may prevent progression to eccentric left ventricular hypertrophy and dilated cardiomyopathy.

Entities:  

Mesh:

Year:  2002        PMID: 12164087      PMCID: PMC4531672          DOI: 10.3904/kjim.2002.17.2.107

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  15 in total

1.  Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients.

Authors: 
Journal:  Am J Kidney Dis       Date:  1992-11       Impact factor: 8.860

2.  Left ventricular function in uremia: echocardiographic and radionuclide assessment in patients on maintenance hemodialysis.

Authors:  K N Lai; J Ng; J Whitford; I Buttfield; R G Fassett; T H Mathew
Journal:  Clin Nephrol       Date:  1985-03       Impact factor: 0.975

Review 3.  Cardiac disease in chronic uremia: pathogenesis.

Authors:  G M London; P S Parfrey
Journal:  Adv Ren Replace Ther       Date:  1997-07

4.  Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Authors:  J D Harnett; R N Foley; G M Kent; P E Barre; D Murray; P S Parfrey
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

Review 5.  Cardiac hypertrophy and arterial alterations in end-stage renal disease: hemodynamic factors.

Authors:  G M London; S J Marchais; A P Guerin; F Metivier; B Pannier
Journal:  Kidney Int Suppl       Date:  1993-06       Impact factor: 10.545

6.  Echocardiographic evaluation of left ventricular dimensions and function in chronic hemodialysis patients with cardiomegaly.

Authors:  A Renger; M Müller; G A Jutzler; L Bette
Journal:  Clin Nephrol       Date:  1984-03       Impact factor: 0.975

7.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

Authors:  R N Foley; P S Parfrey; J D Harnett; G M Kent; C J Martin; D C Murray; P E Barre
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

8.  Impact of left ventricular hypertrophy on survival in end-stage renal disease.

Authors:  J S Silberberg; P E Barre; S S Prichard; A D Sniderman
Journal:  Kidney Int       Date:  1989-08       Impact factor: 10.612

9.  Outcome and risk factors of ischemic heart disease in chronic uremia.

Authors:  P S Parfrey; R N Foley; J D Harnett; G M Kent; D Murray; P E Barre
Journal:  Kidney Int       Date:  1996-05       Impact factor: 10.612

10.  Analysis of left-ventricular changes associated with chronic hemodialysis. A noninvasive follow-up study.

Authors:  J Hüting; W Kramer; G Schütterle; V Wizemann
Journal:  Nephron       Date:  1988       Impact factor: 2.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.